PE20091014A1 - Compuestos espiro y uso farmaceutico de los mismos - Google Patents
Compuestos espiro y uso farmaceutico de los mismosInfo
- Publication number
- PE20091014A1 PE20091014A1 PE2008001826A PE2008001826A PE20091014A1 PE 20091014 A1 PE20091014 A1 PE 20091014A1 PE 2008001826 A PE2008001826 A PE 2008001826A PE 2008001826 A PE2008001826 A PE 2008001826A PE 20091014 A1 PE20091014 A1 PE 20091014A1
- Authority
- PE
- Peru
- Prior art keywords
- spiro
- phenyl
- pharmaceutical use
- spiro compounds
- ilmetoxi
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/86—Unsaturated compounds containing keto groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/50—Spiro compounds
Abstract
SE REIFERE A UN COMPUESTO DE OFRMULA I, DONDE R1 ES H, ALQUILO C1-C6, ALCOXI C1-C6, HIDROXIALQUILO C1-C6, ENTRE OTROS; R2 ES HALOGENO, ALQUILO C1-C6, HIDROXI, HIDROXI, ENTRE OTROS; p ES 0-3; X ES C, N; p ES 0-2; m1 ES 0-2; m2 ES 0-1; n1 ES 0-4; n2 ES 1-4; ---- ES UN ENLACE. SON COMPUESTOS PREFERIDOS: ACIDO 3-ETOXI-3-[4-(ESPIRO[5.5]UNDEC-1-EN-2-ILMETOXI)-FENIL]-PROPIONICO; ACIDO (S)-3-[4-(ESPIRO[5.5]UNDEC-2-EN-2-ILMETOXI)-FENIL]-HEX-4-INOICO; (S)-3-[4-(ESPIRO[5.6]DODEC-2-EN-2-ILMETOXI)-FENIL]-HEX-4-INOICO; ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA DICHOS COMPUESTOS SON AGONISTAS DE GPR40, UTILES EN EL TRATAMIENTO DE DIABETES MELLITUS, HIPERGLICEMIA, ALTERACION DE TOLERANCIA A LA GLUCOSA, ENTRE OTROS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007279697 | 2007-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20091014A1 true PE20091014A1 (es) | 2009-08-17 |
Family
ID=40579581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001826A PE20091014A1 (es) | 2007-10-26 | 2008-10-24 | Compuestos espiro y uso farmaceutico de los mismos |
Country Status (30)
Country | Link |
---|---|
US (3) | US8299296B2 (es) |
EP (3) | EP2202216B1 (es) |
JP (5) | JP4568779B2 (es) |
KR (1) | KR101565622B1 (es) |
CN (1) | CN101835737B (es) |
AR (1) | AR071055A1 (es) |
AU (1) | AU2008314933B2 (es) |
BR (1) | BRPI0818687A2 (es) |
CA (1) | CA2704013C (es) |
CL (1) | CL2008003153A1 (es) |
CO (1) | CO6321230A2 (es) |
CY (1) | CY1113352T1 (es) |
DK (1) | DK2202216T3 (es) |
ES (1) | ES2386596T3 (es) |
HK (1) | HK1144421A1 (es) |
HR (1) | HRP20120696T1 (es) |
IL (1) | IL205283A (es) |
ME (1) | ME02338B (es) |
MX (1) | MX2010004435A (es) |
MY (1) | MY148469A (es) |
NZ (1) | NZ584161A (es) |
PE (1) | PE20091014A1 (es) |
PL (1) | PL2202216T3 (es) |
PT (1) | PT2202216E (es) |
RS (1) | RS52474B (es) |
RU (1) | RU2490250C2 (es) |
SI (1) | SI2202216T1 (es) |
TW (1) | TWI421070B (es) |
WO (1) | WO2009054479A1 (es) |
ZA (1) | ZA201002305B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101679908B (zh) * | 2007-06-11 | 2012-10-24 | 奇华顿股份有限公司 | 有机化合物 |
CL2008003153A1 (es) * | 2007-10-26 | 2009-07-24 | Japan Tobacco Inc | Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras. |
NZ588983A (en) * | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
ES2416462T3 (es) * | 2009-06-29 | 2013-08-01 | Merz Pharma Gmbh & Co. Kgaa | Método de preparación de neramexane. |
JP5749259B2 (ja) | 2009-06-29 | 2015-07-15 | メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー | 1−クロロアセトアミド−1,3,3,5,5−ペンタメチルシクロヘキサンを調製する方法 |
BRPI1012669A2 (pt) * | 2009-06-29 | 2016-04-05 | Merz Pharma Gmbh & Co Kgaa | metodo de preparacao de 3,3,5,5-tetrametliciclohexanona, método de preparção de 1-amino-1,3,3,5,5,-pentametilciclohexano ou um sal farmaceuticamente aceitável do mesmo e composto |
EP2289881A1 (de) * | 2009-08-06 | 2011-03-02 | Boehringer Ingelheim International GmbH | Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen |
AR078522A1 (es) * | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
AR078948A1 (es) | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
WO2011078371A1 (ja) | 2009-12-25 | 2011-06-30 | 持田製薬株式会社 | 新規3-ヒドロキシ-5-アリールイソチアゾール誘導体 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
SG192216A1 (en) | 2011-02-01 | 2013-09-30 | Boehringer Ingelheim Int | 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof |
BR112013027883A2 (pt) | 2011-04-27 | 2017-08-08 | Mochida Pharm Co Ltd | novo derivado de 1-óxido de 3-hidroxiisotiazol |
US9072758B2 (en) | 2011-04-28 | 2015-07-07 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2875020B1 (en) | 2012-07-19 | 2017-09-06 | Boehringer Ingelheim International GmbH | Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one |
EP2911655A1 (en) | 2012-10-24 | 2015-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival |
TWI692469B (zh) | 2012-11-09 | 2020-05-01 | 南韓商Lg化學股份有限公司 | Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
UY35143A (es) | 2012-11-16 | 2014-05-30 | Bristol Myers Squibb Co | Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g |
KR101569522B1 (ko) * | 2013-04-18 | 2015-11-17 | 현대약품 주식회사 | 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
EP3076959B1 (en) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2015119899A1 (en) | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
DK3107901T3 (da) | 2014-02-19 | 2020-06-22 | Piramal Entpr Ltd | Forbindelser til brug som gpr120 agonister |
WO2016012965A2 (en) | 2014-07-25 | 2016-01-28 | Piramal Enterprises Limited | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof |
US10214521B2 (en) | 2014-09-11 | 2019-02-26 | Piramal Enterprises Limited | Fused heterocyclic compounds as GPR120 agonists |
ES2805743T3 (es) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Método y composición farmacéutica para uso en el tratamiento de la diabetes |
CA3058578A1 (en) * | 2017-03-31 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Aromatic compound |
UA126458C2 (uk) | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
TWI732245B (zh) | 2018-07-13 | 2021-07-01 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
BR112022006546A2 (pt) | 2019-10-07 | 2022-08-30 | Kallyope Inc | Agonistas de gpr119 |
MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
CN115181023B (zh) * | 2022-05-17 | 2023-07-28 | 东华理工大学 | 螺环活性增塑剂及其制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4331179A1 (de) * | 1993-09-14 | 1995-03-16 | Hoechst Schering Agrevo Gmbh | Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
RU2191007C2 (ru) * | 1996-05-24 | 2002-10-20 | Лиганд Фармасьютикалз Инкорпорейтед | Способ лечения иhcд агонистами rxr |
GB9927056D0 (en) | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
DE60315776T2 (de) * | 2002-10-14 | 2008-06-05 | Firmenich S.A. | Spiroverbindungen als Duftstoffe |
JP4594611B2 (ja) | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | 受容体機能調節剤 |
CA2505322A1 (en) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONNECTION WITH CONDENSED RING |
JP4922615B2 (ja) | 2003-11-26 | 2012-04-25 | 武田薬品工業株式会社 | 受容体機能調節剤 |
JP4074616B2 (ja) * | 2003-12-25 | 2008-04-09 | 武田薬品工業株式会社 | 3−(4−ベンジルオキシフェニル)プロパン酸誘導体 |
RU2006126978A (ru) | 2003-12-25 | 2008-01-27 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные 3-(4-бензилоксифенил)пропановой кислоты |
ES2433466T3 (es) | 2004-02-27 | 2013-12-11 | Amgen, Inc | Compuestos, composiciones farmacéuticas y métodos para su uso en el tratamiento de trastornos metabólicos |
EP2253315A1 (en) * | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
JP2007284350A (ja) | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | 糖尿病治療剤 |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
AU2006291234A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
US7714008B2 (en) | 2006-09-07 | 2010-05-11 | Amgen Inc. | Heterocyclic GPR40 modulators |
AU2007292816B2 (en) | 2006-09-07 | 2011-11-17 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
CL2008003153A1 (es) * | 2007-10-26 | 2009-07-24 | Japan Tobacco Inc | Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras. |
NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
-
2008
- 2008-10-24 CL CL2008003153A patent/CL2008003153A1/es unknown
- 2008-10-24 PT PT08841970T patent/PT2202216E/pt unknown
- 2008-10-24 KR KR1020107011427A patent/KR101565622B1/ko not_active IP Right Cessation
- 2008-10-24 CN CN2008801132388A patent/CN101835737B/zh not_active Expired - Fee Related
- 2008-10-24 ME MEP-2016-195A patent/ME02338B/me unknown
- 2008-10-24 JP JP2008273676A patent/JP4568779B2/ja active Active
- 2008-10-24 NZ NZ584161A patent/NZ584161A/en not_active IP Right Cessation
- 2008-10-24 CA CA2704013A patent/CA2704013C/en not_active Expired - Fee Related
- 2008-10-24 WO PCT/JP2008/069296 patent/WO2009054479A1/ja active Application Filing
- 2008-10-24 PE PE2008001826A patent/PE20091014A1/es not_active Application Discontinuation
- 2008-10-24 AR ARP080104642A patent/AR071055A1/es not_active Application Discontinuation
- 2008-10-24 ES ES08841970T patent/ES2386596T3/es active Active
- 2008-10-24 EP EP08841970A patent/EP2202216B1/en active Active
- 2008-10-24 MX MX2010004435A patent/MX2010004435A/es active IP Right Grant
- 2008-10-24 RS RS20120400A patent/RS52474B/en unknown
- 2008-10-24 RU RU2010121160/04A patent/RU2490250C2/ru not_active IP Right Cessation
- 2008-10-24 PL PL08841970T patent/PL2202216T3/pl unknown
- 2008-10-24 US US12/258,033 patent/US8299296B2/en active Active
- 2008-10-24 BR BRPI0818687A patent/BRPI0818687A2/pt not_active IP Right Cessation
- 2008-10-24 EP EP12173164A patent/EP2508503A1/en not_active Withdrawn
- 2008-10-24 AU AU2008314933A patent/AU2008314933B2/en not_active Ceased
- 2008-10-24 TW TW097140805A patent/TWI421070B/zh not_active IP Right Cessation
- 2008-10-24 SI SI200830752T patent/SI2202216T1/sl unknown
- 2008-10-24 EP EP13184140.5A patent/EP2684861A3/en not_active Withdrawn
- 2008-10-24 MY MYPI2010001866A patent/MY148469A/en unknown
- 2008-10-24 DK DK08841970.0T patent/DK2202216T3/da active
-
2010
- 2010-03-31 ZA ZA2010/02305A patent/ZA201002305B/en unknown
- 2010-04-22 IL IL205283A patent/IL205283A/en not_active IP Right Cessation
- 2010-05-26 CO CO10062839A patent/CO6321230A2/es active IP Right Grant
- 2010-07-23 JP JP2010165678A patent/JP2010270137A/ja active Pending
- 2010-11-26 HK HK10110999.8A patent/HK1144421A1/xx not_active IP Right Cessation
-
2012
- 2012-08-22 CY CY20121100753T patent/CY1113352T1/el unknown
- 2012-09-04 HR HRP20120696AT patent/HRP20120696T1/hr unknown
- 2012-09-14 US US13/616,389 patent/US20130109710A1/en not_active Abandoned
-
2014
- 2014-08-04 JP JP2014158380A patent/JP2014221829A/ja active Pending
- 2014-11-17 US US14/542,869 patent/US20150299090A1/en not_active Abandoned
-
2016
- 2016-01-06 JP JP2016001396A patent/JP2016102130A/ja not_active Ceased
-
2017
- 2017-03-14 JP JP2017049246A patent/JP2017132787A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20091014A1 (es) | Compuestos espiro y uso farmaceutico de los mismos | |
ECSP088511A (es) | Agonistas del receptor del neuropeptido-2 | |
PE20110288A1 (es) | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol | |
PE20080993A1 (es) | Compuestos ciclicos fusionados como moduladores del receptor gpr40 | |
PE20040655A1 (es) | Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen | |
PE20120002A1 (es) | Derivados de benceno sustituido con glucopiranosilo como inhibidores de sglt2 | |
PE20090938A1 (es) | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo | |
NO20064365L (no) | Terapeutisk forbindelse | |
PE20121474A1 (es) | Nuevos compuestos de espiropiperidina | |
CO6382155A2 (es) | Agonistas del receptor gpr120 de arilo y usos de los mismos | |
NO20084049L (no) | Forbindelser med forsterket ampa receptor og anvendelse derav i medisin | |
PE20110297A1 (es) | Inhibidores de dpp-4 para la cicatrizacion de heridas | |
PE20071094A1 (es) | Derivados 1-ortoflurofenil sustituidos 1,2,5-tiadiazolidindionas como inhibidores de ptpasa | |
PE20110152A1 (es) | Nuevos derivados de sulfamida sustituida | |
UY29182A1 (es) | "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones" | |
PE20081201A1 (es) | Forma cristalina del hemihidrato de 1-(b-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno | |
EA200970726A1 (ru) | Твердый препарат, содержащий алоглиптин и пиоглитазон | |
UY29020A1 (es) | Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina, procedimientos para su preparacinn y su uso.- | |
UY31676A1 (es) | "derivados de 3-metil-imidiazo-[1,2-b]-piridazina" | |
BRPI0508724A (pt) | derivados do fenilaminoetanol como agonistas do receptor beta2 | |
BRPI0610907A2 (pt) | composto ou precursores hidrolisÁveis in vivo ou sal farmaceuticamente aceitÁvel do mesmo, mÉtodos de tratamento ou profilaxia de uma doenÇa ou condiÇço na qual a modulaÇço do receptor de mch1 É benÉfica e de tratamento ou profilaxia de doenÇas, composiÇço farmacÊutica, e, uso de um composto | |
ATE539743T1 (de) | Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan | |
NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
BRPI0518613A2 (pt) | compostos, composiÇço farmacÊutica, mÉtodo de preparar uma composiÇço, e, uso de um composto | |
UY29343A1 (es) | Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |